This SDS packet was issued with item:

078056437

The safety data sheets (SDS) in this packet apply to the individual products listed below. Please refer to invoice for specific item number(s).

078921838

The safety data sheets (SDS) in this packet apply to one or more components included in the items listed below. Items listed below may require one or more SDS. Please refer to invoice for specific item number(s).

078056429



UPDATED PRODUCT CODE: 066999 -12.5mg VERSION DATE: 6/2007

Page 1 of 4

MATERIAL SAFETY DATA SHEET

------ 1. CHEMICAL PRODUCT and COMPANY IDENTIFICATION --------

Product Name: SALIX™ Product Family: PHARMACEUTICALS

PRODUCT:

PRODUCT CODE:

066999 - 12.5 mg

SALIX™ TABLETS

SYNONYMS:

FUROSEMIDE

PRODUCT USE: Refer to product insert for proper usage.

<u>COMPANY ADDRESS</u> - Intervet Inc - 29160 Intervet Lane - Millsboro, DE 19966

------ 2. COMPOSITION / INFORMATION on INGREDIENTS ------

HAZARDOUS COMPONENT:	CONCENTRATION:	CAS NUMBER:
FUROSEMIDE LIQUID	1.0%-5.0%	54-31-9
FUROSEMIDE TABLETS	12.5MG-50MG	54-31-9
3. HAZAP	RDS IDENTIFICATION	

EMERGENCY OVERVIEW: Warning: Milk taken from animals during treatment and for forty-eight hours (four milkings) after the last treatment must not be used for food. Cattle must not be slaughtered for food within forty-eight hours following the last treatment.

SIGNS AND SYMPTOMS OF EXPOSURE: In animals, signs of acute toxicity include lethargy, prostration, diuresis, and weight loss. In humans diuresis should be the first sign of exposure. Excessive diuresis may result in dehydration, hypokalemia, hypocalcemia and orthostatic hypotension. Other symptoms include weakness, fatigue and malaise.

	IUMAN, FIRE, SPILL NIMAL: 1-800-345-4			1-800-228-5635 EXT. 132 24 HRS.
				SPILL, LEAK, FIRE: 1-800-424-9300
PRODUCT INFORMATION:	1-800-835-0541	OR	1-302-934-8051	9:00 A.M 5:00 P.M. EST
Obtained b	y Global Safety Mana	agemer	ıt, 1-813-435-5161 ·	- www.GSMSDS.com



UPDATED PRODUCT CODE:066999 -12.5mgVERSION DATE:6/2007

Page 2 of 4

ROUTES OF ENTRY: Dermal, Injection, Inhalation, Ingestion

ACUTE EFFECTS OF EXPOSURE: May cause irritation at site of contact.

CHRONIC EFFECTS OF EXPOSURE: None known

TARGET ORGAN EFFECTS: Kidney. Furosemide inhibits the absorption of sodium and chlorine in the proximal and distal tubules, and in the loop of Henley.

CARCINOGENIC EFFECTS: This product is not considered a carcinogen and is not listed by OSHA, IRA or NTT.

------ 4. FIRST AID MEASURES ------

Treatment is symptomatic and includes replacement of fluid and electrolytes.

SKIN: Wash immediately affected area with soap and water. Contact a physician.

EYES: Immediately flush with plenty of water for fifteen minutes Contact a physician.

INHALATION: Remove to fresh air. If not breathing, give artificial respiration and call for medical help immediately.

INGESTION: Seek medical attention immediately.

------ 5. FIRE FIGHTING MEASURES ------

FLAMMABILITY: Not Available

EXTINGUISHING METHODS: Use Water, Water Mist, Foam or Dry Chemical to extinguish fire.

FIRE FIGHTING INSTRUCTIONS: Wear full bunker gear, including SCBA. Keep upwind.

------ 6. ACCIDENTAL RELEASE MEASURES------- 6.

PROCEDURES IN CASE OF SPILL OR LEAK: Minor spillage may be flushed away with water. Large volume spills should be collected in salvage containers and should be incinerated in accordance with local, state and federal regulations.

	7.	HANDLING and STORAGE
--	----	----------------------

EMERGENCY:

HUMAN, FIRE, SPILL OR ENVIRONMENTAL: 1-800-228-5635 EXT. 132 24 HRS. ANIMAL: 1-800-345-4735 EXT. 104 24 HRS. CHEMTREC® FOR CHEMICAL EMERGENCY SPILL, LEAK, FIRE: 1-800-424-9300

PRODUCT INFORMATION: 1-800-835-0541 OR 1-302-934-8051 9:00 A.M. - 5:00 P.M. EST



UPDATED PRODUCT CODE:066999 -12.5mgVERSION DATE:6/2007

Page 3 of 4

STORAGE: Store at room temperature (below 25C) in well-closed containers with safety closures. The product should be colorless to slightly brown. Do not use if solution is discolored. Product is light sensitive.

SHELF LIFE: See expiration date on product label.

HANDLING PRECAUTIONS: See product label.

------ 8. EXPOSURE CONTROL / PERSONAL PROTECTION ------

Furosemide Workplace Exposure Limit: (interim) 0.5mg/m3

EYES: Prevent eye contact by wearing appropriate eye protection for handling tasks.

SKIN: Avoid skin contact. Wear chemical resistant gloves, long-sleeves and trousers to prevent dermal contact.

RESPIRATOR PROTECTION: Under normal conditions of use, as stated in the product insert, no respiratory protection is necessary. However, if ventilation is inadequate wear a NIOSH approved respirator.

------ 9. PHYSICAL and CHEMICAL PROPERTIES -------

APPEARANCE: 50mL vials, 12.5mg yellow tablet, or 50mg yellow tablet

PH: 7.0-7.8

------ 10. STABILITY and REACTIVITY ------

CHEMICAL STABILITY: Stable

CONDITIONS TO AVOID: None known

INCOMPATIBILITY: None Known

HAZARDOUS POLYMERIZATION: Will not occur

------ 11. TOXICOLOGICAL INFORMATION ------

EMERGENCY: HUMAN, FIRE, SPILL OR ENVIRONMENTAL: 1-800-228-5635 EXT. 132 24 HRS. ANIMAL: 1-800-345-4735 EXT. 104 24 HRS. CHEMTREC® FOR CHEMICAL EMERGENCY SPILL, LEAK, FIRE: 1-800-424-9300

PRODUCT INFORMATION: 1-800-835-0541 OR 1-302-934-8051 9:00 A.M. – 5:00 P.M. EST



UPDATED PRODUCT CODE:066999 -12.5mgVERSION DATE:6/2007

Page 4 of 4

Oral LD 50 Rat: *4600 mg/kg* Intraperitoneal LD50 (rat): *Not available* Intraperitoneal LD50 (mouse): *Not available*

------ 12. ECOLOGICAL INFORMATION------

ECOTOXITY: Salix (Furosemide) administered to animals presents negligible impact on the environment.

Minor spillage may be flushed away with water. Large volume spills should be collected in salvage containers and should be incinerated in accordance with local, state and federal regulations.

DOT SHIPPING INFORMATION: Not regulated by the DOT

------ 15. REGULATORY INFORMATION------

US FEDERAL REGULATIONS: Salix (Furosemide) is regulated under the US FDA.

------16. OTHER INFORMATION ------

DISCLAIMER:

The information contained herein is true and accurate to the best of the knowledge of Intervet Inc. However, all data, instructions and/or recommendations are made without guarantee. The buyer and handler assume all risk and liability of use, storage and/or handling of this product not in accordance with the terms of the product label.

PRODUCT INFORMATION: 1-800-835-0541 OR 1-302-934-8051 9:00 A.M. - 5:00 P.M. EST





Version 3.2	Revision Date: 04/12/2018		OS Number: 2214-00006	Date of last issue: 10/12/2017 Date of first issue: 05/03/2016		
SECTION	1. IDENTIFICATION					
Prod	uct name	:	Furosemide Injec	tion Formulation		
Manu	ufacturer or supplier's	deta	ails			
Com	pany name of supplier	:	Merck & Co., Inc			
Addro	ess	:	2000 Galloping H Kenilworth - New	lill Road Jersey - U.S.A. 07033		
Telep	Telephone		: 908-740-4000			
Telef	Telefax		: 908-735-1496			
Emei	Emergency telephone		1-908-423-6000			
E-ma	E-mail address		: EHSDATASTEWARD@merck.com			
Reco	ommended use of the o	chen	nical and restricti	ons on use		
Reco	mmended use	:	Veterinary produc	ct		
SECTION	2. HAZARDS IDENTIF	ICA	ΓΙΟΝ			
GHS	classification in accor	rdan	ce with 29 CFR 1	910.1200		
•	ific target organ mic toxicity - repeated sure	:	Category 1 (Kidn	ey, Liver)		

GHS label elements

Hazard pictograms	:

Signal Word :	Danger
Hazard Statements :	H372 Causes damage to organs (Kidney, Liver) through prolonged or repeated exposure.
Precautionary Statements :	Prevention: P260 Do not breathe mist or vapors. P264 Wash skin thoroughly after handling. P270 Do not eat, drink or smoke when using this product.
	Response: P314 Get medical advice/ attention if you feel unwell.
	Disposal: P501 Dispose of contents/ container to an approved waste disposal plant.





/ersion 5.2	Revision Date: 04/12/2018		S Number: 2214-00006	Date of last issue: 10/12/2017 Date of first issue: 05/03/2016		
Other	hazards					
None	known.					
ECTION	3. COMPOSITION/INF	ORN	IATION ON ING	REDIENTS		
Subat	ance / Mixture		Mixturo			
Subsi	ance / Mixture	•	Mixture			
Hazar	dous ingredients					
-	ical name		CAS-No.	Concentration (% w/w)		
Furos	emide		54-31-9	>= 5 - < 10		
ECTION	4. FIRST AID MEASUF	RES				
Conor	al advice		In the case of c	accident or if you feel unwell, seek medical		
Gener		•		ately., When symptoms persist or in all cases of		
lf inha	led	:	If inhaled, remo Get medical att	ove to fresh air. tention if symptoms occur.		
In cas	e of skin contact	:	of water.	act, immediately flush skin with soap and plenty tention if symptoms occur.		
In cas	e of eye contact	:	Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.			
lf swa	llowed	:	If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.			
	mportant symptoms ffects, both acute and ed	:	Causes damage to organs through prolonged or repeated exposure.			
Protec	ction of first-aiders	:	and use the red	nders should pay attention to self-protection, commended personal protective equipment ntial for exposure exists.		
Notes	to physician	:	Treat symptom	atically and supportively.		
ECTION	5. FIRE-FIGHTING ME	ASL	IRES			
Suitab	extinguishing media	:	Water spray Alcohol-resista Carbon dioxide Dry chemical			
Unsuit media	table extinguishing	:	None known.			
Specif fightin	fic hazards during fire g	:	Exposure to co	mbustion products may be a hazard to health.		



Furosemide Injection Formulation

Vers 3.2	ion	Revision Date: 04/12/2018		S Number: 2214-00006	Date of last issue: 10/12/2017 Date of first issue: 05/03/2016
	Hazard ucts	ous combustion prod-	:	Nitrogen oxides (N Carbon oxides Sulfur oxides Chlorine compour	
	Specific ods	extinguishing meth-	:	cumstances and t Use water spray t	measures that are appropriate to local cir- he surrounding environment. o cool unopened containers. ged containers from fire area if it is safe to do
	Special for fire-	protective equipment fighters	:	In the event of fire Use personal prot	e, wear self-contained breathing apparatus. ective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protec- : tive equipment and emer- gency procedures	Use personal protective equipment. Follow safe handling advice and personal protective equipment recommendations.
Environmental precautions :	Discharge into the environment must be avoided. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g., by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
Methods and materials for : containment and cleaning up	Soak up with inert absorbent material. For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures	:	See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
Local/Total ventilation	:	Use only with adequate ventilation.
Advice on safe handling	:	Avoid inhalation of vapor or mist. Do not swallow.



Version 3.2	Revision Date: 04/12/2018	SDS Number: 632214-00006	Date of last issue: 10/12/2017 Date of first issue: 05/03/2016
		Handle in acc practice, base assessment	with eyes. led or repeated contact with skin. ordance with good industrial hygiene and safety ed on the results of the workplace exposure prevent spills, waste and minimize release to the
Cond	litions for safe storage		erly labeled containers. dance with the particular national regulations.
Mate	rials to avoid	: Do not store v Strong oxidizi Organic perov Explosives Gases	

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis
Furosemide	54-31-9	TWA	200 µg/m³	Internal
		TWA	OEB 2 (>=100 -	Internal
			1000 ug/m3)	

Engineering measures	:	Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip- less quick connections). All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Laboratory operations do not require special containment.

Personal protective equipment

Respiratory protection	:	General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.
Hand protection Material	:	Chemical-resistant gloves



Furosemide Injection Formulation

Version 3.2	Revision Date: 04/12/2018	SDS Number: 632214-00006	Date of last issue: 10/12/2017 Date of first issue: 05/03/2016
Eye p	protection	If the work er mists or aero Wear a faces	glasses with side shields or goggles. wironment or activity involves dusty conditions, sols, wear the appropriate goggles. hield or other full face protection if there is a lirect contact to the face with dusts, mists, or
Skin a	and body protection	: Work uniform	or laboratory coat.
Hygie	ene measures	located close When using o Wash contan The effective engineering o appropriate d industrial hyg	eye flushing systems and safety showers are to the working place. do not eat, drink or smoke. ninated clothing before re-use. operation of a facility should include review of controls, proper personal protective equipment, egowning and decontamination procedures, iene monitoring, medical surveillance and the istrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	Aqueous solution
Color	:	yellow
Odor	:	No information available.
Odor Threshold	:	No data available
рН	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	No data available
Relative vapor density	:	No data available



Furosemide Injection Formulation

Version 3.2	Revision Date: 04/12/2018		S Number: 2214-00006	Date of last issue: 10/12/2017 Date of first issue: 05/03/2016
Relativ	e density	:	No data available	e
Densit	у	:	No data available	9
	lity(ies) ter solubility	:	No data available	9
	on coefficient: n- I/water	:	No data available	9
Autoig	nition temperature	:	No data available	9
Decom	position temperature	:	No data available	9
Viscos Visc	ity cosity, kinematic	:	No data available	9
Explos	ive properties	:	Not explosive	
Oxidizi	ng properties	:	The substance o	r mixture is not classified as oxidizing.
Particle	e size	:	Not applicable	

SECTION 10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reac- tions	:	Can react with strong oxidizing agents.
Conditions to avoid	:	None known.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation Skin contact Ingestion Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity

: Acute toxicity estimate: > 5,000 mg/kg



/ersion 8.2	Revision Date: 04/12/2018	-	DS Number: 2214-00006	Date of last issue: 10/12/2017 Date of first issue: 05/03/2016
			Method: Calculati	on method
Com	ponents:			
	semide:			
Acut	e oral toxicity	:	LD50 (Rat): 2,600) mg/kg
			LD50 (Dog): 2,00	0 mg/kg
			LD50 (Rabbit): 80	0 mg/kg
	e toxicity (other routes of inistration)	:	LD0 (Humans): 6 Application Route	
			LD50 (Rat): 800 r Application Route	
Skin	corrosion/irritation			
	classified based on availa			
	ous eye damage/eye irri classified based on availa			
	piratory or skin sensitiz			
_	sensitization			
	classified based on availa	ble	information.	
-	biratory sensitization classified based on availa	ble	information.	
	n cell mutagenicity			
	classified based on availa	ble	information.	
	ponents:			
	semide: ptoxicity in vitro	:	Test Type: Bacter Result: negative	ial reverse mutation assay (AMES)
				o mammalian cell gene mutation test se lymphoma cells
			Test Type: DNA c thesis in mammal Test system: man Result: negative	
				nosome aberration test in vitro nese hamster ovary cells
			Test Type: In vitro malian cells	sister chromatid exchange assay in mam-



sion	Revision Date: 04/12/2018	SDS Number: 632214-00006	Date of last issue: 10/12/2017 Date of first issue: 05/03/2016
		Test system: (Result: negativ	Chinese hamster cells ve
Geno	toxicity in vivo	: Test Type: Ma cytogenetic as Species: Mous Application Ro Result: negativ	se Dute: Ingestion
			oute: Ingestion
	nogenicity lassified based on a	vailable information.	
<u>Com</u>	<u>oonents:</u>		
Furos	semide:		
	cation Route sure time L	: Rat : Ingestion : 104 weeks : 16 mg/kg body : equivocal	y weight
	cation Route sure time EL	: Mouse : Ingestion : 2 Years : 91 mg/kg body : positive	y weight
IARC			sent at levels greater than or equal to 0.1% is or confirmed human carcinogen by IARC.
OSH/		onent of this product pro a's list of regulated carci	esent at levels greater than or equal to 0.1% is nogens.
NTP		dient of this product pres as a known or anticipat	sent at levels greater than or equal to 0.1% is ed carcinogen by NTP.
•	oductive toxicity lassified based on a	vailable information.	
	oonents:		
Furos	semide:		
Effect	ts on fertility	Species: Rat Application Ro General Toxic	e-generation reproduction toxicity study oute: Ingestion ity Parent: NOAEL: 90 mg/kg body weight ects on reproduction parameters.



sion	Revision Date: 04/12/2018	SDS Number: 632214-00006	Date of last issue: 10/12/2017 Date of first issue: 05/03/2016
		Species: Mous Application Ro General Toxic	ne-generation reproduction toxicity study se bute: Ingestion ity Parent: NOAEL: 200 mg/kg body weight ects on reproduction parameters.
Effects	on fetal developmen	Species: Rat Application Ro General Toxic Developmenta Result: No em	rtility/early embryonic development oute: Ingestion ity Maternal: LOAEL: 50 mg/kg body weight al Toxicity: NOAEL: 300 mg/kg body weight ibryotoxic effects., No teratogenic effects. rtility/early embryonic development
		Application Ro General Toxic	bute: Ingestion hity Maternal: LOAEL: 25 mg/kg body weight nal toxicity observed., Fetal effects.
		Species: Rabb Application Ro General Toxic Developmenta	rtility/early embryonic development bit bute: Ingestion ity Maternal: LOAEL: <= 12 mg/kg body weight al Toxicity: LOAEL: 12.5 mg/kg body weight hal toxicity observed., Reduced number of viable
		Species: Rabb Application Ro General Toxic	rtility/early embryonic development bit bute: Ingestion ity Maternal: LOAEL: 15 mg/kg body weight nal toxicity observed., No effects on fetal
STOT-	single exposure		
Not cla	ssified based on ava	lable information.	
STOT-	repeated exposure		
		Kidney, Liver) throug	h prolonged or repeated exposure.
Comp	onents:		
	of exposure Organs	•	duce significant health effects in animals at con- 10 mg/kg bw or less.
Repea	ted dose toxicity		
-	onents:		
<u>Comp</u> e			
<u>Comp</u> Furose	emide:		



Furosemide Injection Formulation

Revision Date: 04/12/2018		••••
ation Route ure time Organs oms	8 mg/kg Ingestion 12 Months Kidney Blood disorders Significant toxicity observed in testing	
•		
ence with human e	sure	
onents:		
emide:		
ion	Remarks: May be harmful if inhaled.	
ontact	Remarks: May irritate skin.	
ontact	Remarks: May cause eye irritation.	
on	Symptoms: Kidney disorders, Headacl ance, dry mouth, hearing loss, Irregula trointestinal disturbance, hypotension	
	04/12/2018 6 ation Route : ure time : Organs : oms : ks : ation toxicity assified based on available	04/12/2018 632214-00006 Date of first issue: 0

Ecotoxicity

Components:

Furosemide:

Toxicity to fish

: LC50: 500 mg/l Exposure time: 96 h

Persistence and degradability

No data available

Bioaccumulative potential

Components:

Furosemide: Partition coefficient: n- : log Pow: 2.03 octanol/water

Mobility in soil

No data available

Other adverse effects No data available

10 / 13





Version 3.2	Revision Date: 04/12/2018		DS Number: 2214-00006	Date of last issue: 10/12/2017 Date of first issue: 05/03/2016
SECTION	13. DISPOSAL CONS	IDEF	ATIONS	
Dispo	sal methods			
Waste	e from residues	:	Dispose of in a	ccordance with local regulations.
Conta	minated packaging	:	handling site fo	rs should be taken to an approved waste r recycling or disposal. specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG Not regulated as a dangerous good

IATA-DGR Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

49 CFR Not regulated as a dangerous good

SECTION 15. REGULATORY INFORMATION

EPCRA - Emergency Planning and Community Right-to-Know

CERCLA Reportable Quantity

This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards	:	Specific target organ toxicity (single or repeated exposure)
SARA 313	:	This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.


US State Regulations	
Pennsylvania Right To Know	
Water	7732-18-5
Furosemide	54-31-9





Version 3.2	Revision Date: 04/12/2018	SDS Number: 632214-00006	Date of last issue: 10/12/2017 Date of first issue: 05/03/2016
Califo	ornia Prop. 65		
	roduct does not conta or any other reproduc	,	known to the State of California to cause cancer,
The ir	ngredients of this pr	oduct are reporte	ed in the following inventories:
AICS		: not determ	ined
DSL		: not determ	ined
IECSO	C	: not determ	ined

SECTION 16. OTHER INFORMATION



HMIS® IV:



HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

AICS - Australian Inventory of Chemical Substances; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC -International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Oth-



Version	Revision Date:	SDS Number:	Date of last issue: 10/12/2017
3.2	04/12/2018	632214-00006	Date of first issue: 05/03/2016

erwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG -United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to	:	Internal technical data, data from raw material SDSs, OECD
compile the Material Safety		eChem Portal search results and European Chemicals Agen-
Data Sheet		cy, http://echa.europa.eu/

Revision Date : 04/12/2018

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8





Version 4.0	Revision Date: 04/12/2018	SDS Num 645633-0		Date of last issue: 10/12/2017 Date of first issue: 05/03/2016	
SECTION	1. IDENTIFICATION				
Prod	uct name	: Furos	emide Solid	Formulation	
Manı	ufacturer or supplier's	details			
Com	pany name of supplier	: Merck	& Co., Inc		
Addro	ess		Galloping H vorth - New	ill Road Jersey - U.S.A. 07033	
Telep	phone	: 908-74	40-4000		
Telef	Telefax		35-1496		
Emei	rgency telephone	: 1-908-	-423-6000		
E-ma	ail address	: EHSD	: EHSDATASTEWARD@merck.com		
Reco	ommended use of the	chemical ar	nd restriction	ons on use	
Reco	mmended use	: Veteri	nary produc	ot	
SECTION	2. HAZARDS IDENTIF	ICATION			
GHS	classification in acco	rdance with	29 CFR 19	010.1200	
Com	bustible dust				
	ific target organ mic toxicity - repeated sure	: Categ	ory 1 (Kidne	ey, Liver)	
GHS	label elements				
Haza	rd pictograms	ms : 🔨			

Hazard pictograms	:	
Signal Word	:	Danger
Hazard Statements	:	If small particles are generated during further processing, handling or by other means, may form combustible dust concentrations in air. H372 Causes damage to organs (Kidney, Liver) through prolonged or repeated exposure.
Precautionary Statements	:	Prevention: P260 Do not breathe dust. P264 Wash skin thoroughly after handling. P270 Do not eat, drink or smoke when using this product.
		Response: P314 Get medical advice/ attention if you feel unwell.



Version	Revision Date:	SDS Number:	Date of last issue: 10/12/2017
4.0	04/12/2018	645633-00005	Date of first issue: 05/03/2016

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards

Dust contact with the eyes can lead to mechanical irritation. Contact with dust can cause mechanical irritation or drying of the skin.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Hazardous ingredients

Chemical name	CAS-No.	Concentration (% w/w)
Starch	9005-25-8	>= 50 - < 70
Furosemide	54-31-9	>= 10 - < 20
Cellulose	9004-34-6	>= 1 - < 5

SECTION 4. FIRST AID MEASURES

General advice	:	In the case of accident or if you feel unwell, seek medical advice immediately., When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	:	If inhaled, remove to fresh air. Get medical attention if symptoms occur.
In case of skin contact	:	In case of contact, immediately flush skin with soap and plenty of water. Get medical attention if symptoms occur.
In case of eye contact	:	If in eyes, rinse well with water. Get medical attention if irritation develops and persists.
If swallowed	:	If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	:	Causes damage to organs through prolonged or repeated exposure. Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation.
Protection of first-aiders	:	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists.
Notes to physician	:	Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES



Furosemide Solid Formulation

Versior 4.0	ı	Revision Date: 04/12/2018		9S Number: 5633-00005	Date of last issue: 10/12/2017 Date of first issue: 05/03/2016
Su	Suitable extinguishing media		:	Water spray Alcohol-resistant foam Carbon dioxide (CO2) Dry chemical	
	nsuita edia	able extinguishing	:	None known.	
	becifi hting	c hazards during fire	:	concentrations, ar potential dust exp	dust; fine dust dispersed in air in sufficient nd in the presence of an ignition source is a losion hazard. pustion products may be a hazard to health.
Ha uc		lous combustion prod-	:	Nitrogen oxides (N Carbon oxides Sulfur oxides Chlorine compour	
Sp od		c extinguishing meth-	:	cumstances and t Use water spray t	measures that are appropriate to local cir- he surrounding environment. o cool unopened containers. ged containers from fire area if it is safe to do
•		l protective equipment fighters	:	In the event of fire Use personal prot	e, wear self-contained breathing apparatus. ective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protec- tive equipment and emer- gency procedures	:	Use personal protective equipment. Follow safe handling advice and personal protective equipment recommendations.
Environmental precautions	:	Discharge into the environment must be avoided. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
Methods and materials for containment and cleaning up	:	Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.



Furosemide Solid Formulation

Version 4.0	Revision Date: 04/12/2018	SDS Number: 645633-00005		Date of last issue: 10/12/2017 Date of first issue: 05/03/2016	
SECTION	I 7. HANDLING AND ST	ORAG	E		
Technical measures		ca P	Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.		
Loca	I/Total ventilation	: U	se only with ade	quate ventilation.	
Advid	Advice on safe handling : Do not breathe du Do not swallow. Avoid contact with Avoid prolonged of Handle in accorda practice, based or assessment Minimize dust ger Keep container cli Keep away from h Take precautiona				
Cond	litions for safe storage			abeled containers. ce with the particular national regulations.	
Mate	rials to avoid	S O E	o not store with trong oxidizing a rganic peroxides xplosives ases		

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis
Starch	9005-25-8	TWA	10 mg/m³	ACGIH
		TWA (Res- pirable)	5 mg/m³	NIOSH REL
		TWA (total)	10 mg/m³	NIOSH REL
		TWA (total dust)	15 mg/m³	OSHA Z-1
		TWA (respir- able fraction)	5 mg/m³	OSHA Z-1
Furosemide	54-31-9	TWA	200 µg/m³	Internal
		TWA	OEB 2 (>=100 - 1000 ug/m3)	Internal
Cellulose	9004-34-6	TWA	10 mg/m ³	ACGIH
		TWA (Res- pirable)	5 mg/m³	NIOSH REL



/ersion .0			OS Number: 5633-00005	17 16		
<u>II</u>				TWA (total)	10 mg/m³	NIOSH REL
				TWA (total dust)	15 mg/m³	OSHA Z-1
				TWA (respir- able fraction)	5 mg/m³	OSHA Z-1
Engir	neering measures	:	compound. All engineerin design and op	g controls should	rols to minimize e d be implemented dance with GMP p d the environmen	by facility by facility
Perso	onal protective equip	ment				
Kesp	iratory protection	:	maintain vapo concentrations unknown, app Follow OSHA use NIOSH/M by air purifying hazardous cho supplied respi release, expos	r exposures belo s are above reco ropriate respirat respirator regula SHA approved r g respirators aga emical is limited rator if there is a sure levels are u where air purifyi	ntilation is recommended ow recommended ory protection she ations (29 CFR 19 respirators. Prote- ainst exposure to . Use a positive p any potential for us inknown, or any of ng respirators ma	d limits. Where or are ould be worn. 910.134) and ction provided any ressure air ncontrolled other
	protection aterial	:	Chemical-resi	stant gloves		
Eye p	protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.			
Skin a	and body protection	:	Work uniform	or laboratory co	at.	
Hygie	ene measures	:	located close When using d Wash contam The effective engineering c appropriate de industrial hygi	to the working p o not eat, drink o inated clothing b operation of a fa ontrols, proper p egowning and de	or smoke. before re-use. cility should inclu ersonal protective econtamination pl medical surveilla	de review of e equipment, rocedures,

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance

: powder



Furosemide Solid Formulation

Versi 4.0	ion	Revision Date: 04/12/2018		S Number: 633-00005	Date of last issue: 10/12/2017 Date of first issue: 05/03/2016
	Color		:	yellow	
	Odor		:	No information av	vailable.
	Odor Tl	nreshold	:	No data available)
	pН		:	No data available	
	Melting	point/freezing point	:	No data available	
	Initial bo range	oiling point and boiling	:	No data available	3
	Flash p	oint	:	Not applicable	
	Evapora	ation rate	:	No data available	
	Flamma	ability (solid, gas)	:	May form explosi handling or other	ve dust-air mixture during processing, means.
	Flamma	ability (liquids)	:	No data available	
	Upper e flamma	explosion limit / Upper bility limit	:	No data available	3
		explosion limit / Lower bility limit	:	No data available	
	Vapor p	pressure	:	No data available	9
	Relative	e vapor density	:	No data available)
	Relative	e density	:	No data available	
	Density		:	No data available	
	Solubili Wate	ty(ies) er solubility	:	No data available	9
	Partition octanol	n coefficient: n- /water	:	No data available	3
	Autoign	ition temperature	:	No data available	9
	Decom	position temperature	:	No data available)
	Viscosit Visc	ty osity, kinematic	:	No data available	9
	Explosi	ve properties	:	Not explosive	
	Oxidizir	ng properties	:	The substance of	r mixture is not classified as oxidizing.
	Molecu	lar weight	:	Not applicable	



Furosemide Solid Formulation

Version 4.0	Revision Date: 04/12/2018		S Number: 5633-00005	Date of last issue: 10/12/2017 Date of first issue: 05/03/2016		
Parti	icle size	:	No data available	e		
SECTION	N 10. STABILITY AND RE	EAC	ΤΙVITY			
Rea	ctivity	:	Not classified as	a reactivity hazard.		
Che	mical stability	:	Stable under nor	mal conditions.		
Poss	sibility of hazardous reac- s	:	handling or other	ive dust-air mixture during processing, r means. trong oxidizing agents.		
Con	ditions to avoid	:	: Heat, flames and sparks. Avoid dust formation.			
Inco	mpatible materials	:	Oxidizing agents			
	ardous decomposition lucts	:	No hazardous de	ecomposition products are known.		
Eye Acu	stion contact te toxicity	blai	information			
	classified based on availa	blei	information.			
	<u>duct:</u> te oral toxicity	:	Acute toxicity esti Method: Calculati	mate: > 5,000 mg/kg on method		
Com	nponents:					
Star Acut	r ch: te oral toxicity	:	LD50 (Mouse): >	5,000 mg/kg		
Furc	osemide:					
Acut	te oral toxicity	:	LD50 (Rat): 2,600) mg/kg		
			LD50 (Dog): 2,00	0 mg/kg		
			LD50 (Rabbit): 80)0 mg/kg		
	te toxicity (other routes of inistration)	:	LD0 (Humans): 6 Application Route			
			LD50 (Rat): 800 r Application Route			



Furosemide Solid Formulation

Version 4.0	Revision Date: 04/12/2018		lumber: 3-00005	Date of last issue: 10/12/2017 Date of first issue: 05/03/2016			
II							
Cellu	llose:						
Acute	e oral toxicity	: LD	50 (Rat): > 5	000 mg/kg			
Acute	e inhalation toxicity	Ex	50 (Rat): > 5. posure time: st atmospher	4 h			
Acute	e dermal toxicity	As	: LD50 (Rabbit): > 2,000 mg/kg Assessment: The substance or mixture has no acute dermal toxicity				
II Skin	corrosion/irritation						
Not c	lassified based on ava	ailable info	rmation.				
Com	ponents:						
Cellu	llose:						
Resu		: No	skin irritation	1			
Rema	arks	: Ba	sed on data f	rom similar materials			
Cellu Resu			eye irritation				
Rema	arks	: Ba	sed on data f	rom similar materials			
Resp	piratory or skin sensi	tization					
Skin	sensitization						
	lassified based on ava	ailable info	rmation.				
Resp	piratory sensitization						
Not c	lassified based on ava	ailable info	rmation.				
Com	ponents:						
Cellu	llose:						
Test Route Spec Meth Resu Resu	es of exposure ies od It	: Sk : Mo : OE : ne	in contact ouse CD Test Gui gative	le assay (LLNA) deline 429 rom similar materials			
	n cell mutagenicity						
	lassified based on ava	ailable info	rmation.				
<u>Com</u>	ponents:						

Furosemide:





vitro :	Result: negative Test Type: In Y Test system: r Result: positive Test Type: DN thesis in mam Test system: r Result: negative Test Type: Ch Test system: 0 Result: positive Test Type: In Y malian cells	vitro mammalian cell gene mutation test mouse lymphoma cells ve NA damage and repair, unscheduled DNA syn- malian cells (in vitro) mammalian liver cells ve promosome aberration test in vitro Chinese hamster ovary cells
	Test system: r Result: positiv Test Type: DN thesis in mam Test system: r Result: negativ Test Type: Ch Test system: 0 Result: positiv Test Type: In malian cells	mouse lymphoma cells /e NA damage and repair, unscheduled DNA syn- malian cells (in vitro) mammalian liver cells ve nromosome aberration test in vitro Chinese hamster ovary cells /e
	thesis in mam Test system: r Result: negati Test Type: Ch Test system: (Result: positiv Test Type: In malian cells	malian cells (in vitro) mammalian liver cells ve nromosome aberration test in vitro Chinese hamster ovary cells ⁄e
	Test system: (Result: positiv Test Type: In malian cells	Chinese hamster ovary cells /e
	malian cells	vitro sister chromatid exchange assay in mam-
	Test system: (Result: negati	Chinese hamster cells
<i>v</i> ivo :	cytogenetic as Species: Mous	se Dute: Ingestion
	cytogenetic te Species: Chin	oute: Ingestion
vitro :	Result: negati	icterial reverse mutation assay (AMES) ve sed on data from similar materials
<i>i</i> ivo :	cytogenetic as Species: Mous Application Ro Result: negati	se pute: Ingestion
	rivo :	rivo : Test Type: Ma cytogenetic as Species: Mou Application Ro Result: negati Remarks: Bas

Components:

Furosemide:

Species Application Route Exposure time	: Rat
Application Route	: Ingestion
Exposure time	: 104 weeks

9/15



Version 4.0	Revision Date: 04/12/2018	SDS Number:Date of last issue: 10/12/2017645633-00005Date of first issue: 05/03/2016	
LOAEI Result		: 16 mg/kg body weight : equivocal	
	ation Route ure time -	 Mouse Ingestion 2 Years 91 mg/kg body weight positive 	
IARC		t of this product present at levels greater than or equal to 0.1% is probable, possible or confirmed human carcinogen by IARC.	
OSHA		ent of this product present at levels greater than or equal to 0.1% is is st of regulated carcinogens.	
NTP		t of this product present at levels greater than or equal to 0.1% is a known or anticipated carcinogen by NTP.	
Not cla <u>Comp</u> Furos	ductive toxicity assified based on a onents: emide:		
Effects	s on fertility	 Test Type: One-generation reproduction toxicity study Species: Rat Application Route: Ingestion General Toxicity Parent: NOAEL: 90 mg/kg body weight Result: No effects on reproduction parameters. Test Type: One-generation reproduction toxicity study Species: Mouse Application Route: Ingestion General Toxicity Parent: NOAEL: 200 mg/kg body weight Result: No effects on reproduction parameters. 	
Effects	on fetal developm	: Test Type: Fertility/early embryonic development Species: Rat Application Route: Ingestion General Toxicity Maternal: LOAEL: 50 mg/kg body weight Developmental Toxicity: NOAEL: 300 mg/kg body weight Result: No embryotoxic effects., No teratogenic effects.	
		Test Type: Fertility/early embryonic development Species: Mouse Application Route: Ingestion General Toxicity Maternal: LOAEL: 25 mg/kg body weight Result: Maternal toxicity observed., Fetal effects.	
		Test Type: Fertility/early embryonic development Species: Rabbit Application Route: Ingestion General Toxicity Maternal: LOAEL: <= 12 mg/kg body weight Developmental Toxicity: LOAEL: 12.5 mg/kg body weight Result: Maternal toxicity observed., Reduced number of viabl	

10 / 15



/ersion I.0	Revision Date: 04/12/2018	SDS Number: 645633-00005	Date of last issue: 10/12/2017 Date of first issue: 05/03/2016
Ш		fetuses.	
		Species: Rabbi Application Rou General Toxicit	
STOT	-single exposure		
Not cl	assified based on av	ailable information.	
STOT	-repeated exposure)	
Cause	es damage to organs	(Kidney, Liver) through	prolonged or repeated exposure.
Comp	oonents:		
Furos	semide:		
Targe	es of exposure et Organs ssment	•	ice significant health effects in animals at con- 0 mg/kg bw or less.
Repe	ated dose toxicity		
<u>Comp</u>	oonents:		
Furos	semide:		
Expos	EL EL sution Route sure time to Organs toms	: Dog : 4 mg/kg : 8 mg/kg : Ingestion : 12 Months : Kidney : Blood disorders : Significant toxic	ity observed in testing
Cellu	lose:		
	EL cation Route sure time	: Rat : > 5,000 mg/kg : Ingestion : 90 Days : Based on data t	from similar materials
-	ation toxicity assified based on av	ailable information.	
Expe	rience with human e	exposure	
Comp	oonents:		
Furos	semide:		
Inhala		: Remarks: May	be harmful if inhaled.



Furosemide Solid Formulation

Version 4.0	Revision Date: 04/12/2018	SDS Number: 645633-00005	Date of last issue: 10/12/2017 Date of first issue: 05/03/2016		
Skin	contact	: Remarks: Ma	y irritate skin.		
Eye c	contact	: Remarks: May	/ cause eye irritation.		
Ingestion		ance, dry mou	dney disorders, Headache, electrolyte imbal- ith, hearing loss, Irregular cardiac activity, Gas- sturbance, hypotension		
SECTION 12. ECOLOGICAL INFORMATION					

Ecotoxicity		
Components:		
Furosemide: Toxicity to fish	:	LC50: 500 mg/l Exposure time: 96 h
Cellulose:		
Toxicity to fish	:	LC50 (Cyprinus carpio (Carp)): > 100 mg/l Exposure time: 96 h Method: OECD Test Guideline 203 Remarks: Based on data from similar materials
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): > 100 mg/l Exposure time: 48 h Method: OECD Test Guideline 202 Remarks: Based on data from similar materials
Toxicity to algae	:	EC50 (Pseudokirchneriella subcapitata (green algae)): > 100 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: Based on data from similar materials
Persistence and degradability	ty	
Components:		
Cellulose:		
Biodegradability	:	Result: Readily biodegradable.
Bioaccumulative potential		
Components:		
Furosemide: Partition coefficient: n- octanol/water	:	log Pow: 2.03
Mobility in soil No data available		





Version 4.0	Revision Date: 04/12/2018		DS Number: 15633-00005	Date of last issue: 10/12/2017 Date of first issue: 05/03/2016				
••	Other adverse effects No data available							
SECTION	SECTION 13. DISPOSAL CONSIDERATIONS							
•	osal methods e from residues	:	Dispose of in acc	cordance with local regulations.				
Conta	aminated packaging	:	handling site for	s should be taken to an approved waste recycling or disposal. specified: Dispose of as unused product.				

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code Not applicable for product as supplied.

Domestic regulation

49 CFR Not regulated as a dangerous good

SECTION 15. REGULATORY INFORMATION

EPCRA - Emergency Planning and Community Right-to-Know

CERCLA Reportable Quantity

This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.


SARA 311/312 Hazards	:	Combustible dust Specific target organ toxicity (single or repeated exposure)
SARA 313	:	This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.



Version 4.0	Revision Date: 04/12/2018	SDS Number: 645633-00005	Date of last issue: 10/12/2017 Date of first issue: 05/03/2016			
US S	tate Regulations					
Pennsylvania Right To Know						
	Starch D-Glucose, 4-O Furosemide Cellulose	betaD-galactopyra	9005-25-8 nosyl-, monohydrate 64044-51-5 54-31-9 9004-34-6			
Calif	ornia Prop. 65					
This product does not contain any chemicals known to the State of California to cause cancer, birth, or any other reproductive defects.						
California Permissible Exposure Limits for Chemical Contaminants						
	Starch Cellulose		9005-25-8 9004-34-6			
The ingredients of this product are reported in the following inventories:						
AICS		: not determir	ed			
DSL		: not determir	ed			
IECS	С	: not determir	ed			

SECTION 16. OTHER INFORMATION

Further information



HMIS® IV:



HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

ACGIH		USA. ACGIH Threshold Limit Values (TLV)
NIOSH REL	:	USA. NIOSH Recommended Exposure Limits
OSHA Z-1	:	USA. Occupational Exposure Limits (OSHA) - Table Z-1 Lim-
		its for Air Contaminants
ACGIH / TWA	:	8-hour, time-weighted average
NIOSH REL / TWA	:	Time-weighted average concentration for up to a 10-hour workday during a 40-hour workweek
OSHA Z-1 / TWA	:	8-hour time weighted average



Furosemide Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/12/2017
4.0	04/12/2018	645633-00005	Date of first issue: 05/03/2016

AICS - Australian Inventory of Chemical Substances; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC -International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG -United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to	:	Internal technical data, data from raw material SDSs, OECD
compile the Material Safety		eChem Portal search results and European Chemicals Agen-
Data Sheet		cy, http://echa.europa.eu/

Revision Date : 04/12/2018

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8